Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance

(2016) D. Zheng et al.   Scientific Reports

Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease

(2015) A Szpechcinski et al.   BRITISH JOURNAL OF CANCER

Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

(2015) Bin-Chi Liao et al.   CURRENT OPINION IN ONCOLOGY

Role of Rebiopsy in Relapsed Non-Small Cell Lung Cancer for Directing Oncology Treatments

(2015) Antti P. Jekunen   Journal of Oncology

Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations

(2014) Youngjoo Lee et al.   CANCER

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

(2014) G. R. Oxnard et al.   CLINICAL CANCER RESEARCH

Circulating Tumor DNA as a Liquid Biopsy for Cancer

(2014) E. Heitzer et al.   CLINICAL CHEMISTRY

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

(2014) Jean-Yves Douillard et al.   Journal of Thoracic Oncology

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)

(2014) Christos Chouaid et al.   LUNG CANCER

Liquid biopsy: monitoring cancer-genetics in the blood

(2013) Emily Crowley et al.   Nature Reviews Clinical Oncology

Urine Cell-Free DNA Integrity as a Marker for Early Prostate Cancer Diagnosis: A Pilot Study

(2013) Valentina Casadio et al.   Biomed Research International

BEAMing Up Personalized Medicine: Mutation Detection in Blood

(2012) A. L. Richardson et al.   CLINICAL CANCER RESEARCH

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling

(2011) J. Chmielecki et al.   Science Translational Medicine

Detection of Mutated K-rasDNA in Urine, Plasma, and Serum of Patients with Colorectal Carcinoma or Adenomatous Polyps

(2009) Ying-Hsiu Su et al.   Annals of the New York Academy of Sciences

Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non–Small-Cell Lung Cancer

(2009) Hua Bai et al.   JOURNAL OF CLINICAL ONCOLOGY

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Circulating mutant DNA to assess tumor dynamics

(2008) Frank Diehl et al.   NATURE MEDICINE

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

(2008) Shyamala Maheswaran et al.   NEW ENGLAND JOURNAL OF MEDICINE